Richard Porter
Chief Tech/Sci/R&D Officer at UNIQURE N.V.
Net worth: 150 801 $ as of 29/04/2024
Profile
Richard Porter is the founder of uniQure France SAS, which was founded in 2019.
He held the title of Chief Executive Officer & Director at uniQure France SAS.
Currently, Dr. Porter is the Chief Business & Scientific Officer at uniQure NV, starting in 2021.
Dr. Porter's former positions include General Manager-Product at Shire Plc from 2011 to 2014, Global Head-Scientific Business Strategy at Roche Group from 2014 to 2016, and Chief Operating Officer at Therachon AG from 2016 to 2019.
Dr. Porter obtained a doctorate degree from The University of Southampton.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
UNIQURE N.V.
0.07% | 30/03/2024 | 33,216 ( 0.07% ) | 150 801 $ | 29/04/2024 |
Richard Porter active positions
Companies | Position | Start |
---|---|---|
UNIQURE N.V. | Chief Tech/Sci/R&D Officer | 04/10/2023 |
Former positions of Richard Porter
Companies | Position | End |
---|---|---|
Therachon AG | Chief Operating Officer | 30/06/2019 |
Roche Group
Roche Group Real Estate DevelopmentFinance Roche Group manages real estate properties. The company designs, develops and constructs residential, commercial and industrial properties. It also provides property management services. The company is headquartered in Basel, Switzerland. | Chief Tech/Sci/R&D Officer | 31/07/2016 |
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | Corporate Officer/Principal | 31/01/2014 |
Corlieve Therapeutics SAS
Corlieve Therapeutics SAS Pharmaceuticals: MajorHealth Technology Corlieve Therapeutics SAS provides neurology services. The company was founded by Richard Porter, Valerie Crepel and Christophe Mulle in November 2019 and is headquartered in Paris, France. | Founder | - |
Training of Richard Porter
The University of Southampton | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
UNIQURE N.V. | Health Technology |
Private companies | 4 |
---|---|
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | Commercial Services |
Roche Group
Roche Group Real Estate DevelopmentFinance Roche Group manages real estate properties. The company designs, develops and constructs residential, commercial and industrial properties. It also provides property management services. The company is headquartered in Basel, Switzerland. | Finance |
Therachon AG | |
Corlieve Therapeutics SAS
Corlieve Therapeutics SAS Pharmaceuticals: MajorHealth Technology Corlieve Therapeutics SAS provides neurology services. The company was founded by Richard Porter, Valerie Crepel and Christophe Mulle in November 2019 and is headquartered in Paris, France. | Health Technology |
- Stock Market
- Insiders
- Richard Porter